Weight Loss Medications
We prescribe FDA‑approved GLP‑1 medications — Zepbound® and Wegovy® — to help you achieve safe, sustainable weight loss under physician supervision.
How GLP‑1 Medications Work
GLP‑1 (glucagon‑like peptide‑1) medications mimic a natural hormone your body produces after eating, helping regulate appetite and metabolism.
Mechanism of Action
GLP‑1 medications slow stomach emptying, reduce appetite and cravings, improve insulin sensitivity, and support healthy blood sugar levels — working with your body’s natural systems rather than against them.
Proven Effectiveness
In large‑scale clinical trials, patients on Zepbound® lost up to 22.5% of their body weight and patients on Wegovy® lost an average of 15%. These are among the most effective weight loss medications ever studied.
A next‑generation dual‑action GLP‑1 medication for weight loss.
Dual GIP/GLP‑1 Action
Zepbound® is the only FDA‑approved weight loss medication that targets both GIP and GLP‑1 receptors, addressing two key hormones involved in appetite regulation and metabolism.
Up to 22.5% Weight Loss
In the SURMOUNT clinical trial program, patients on the highest dose of Zepbound® lost up to 22.5% of their body weight over 72 weeks, with many patients achieving over 20% weight loss.
Once‑Weekly Injection
Zepbound® is administered as a simple once‑weekly subcutaneous injection using a pre‑filled pen. Doses are gradually increased over several weeks to minimize side effects.
Additional Health Benefits
Beyond weight loss, Zepbound® has shown improvements in blood sugar control, blood pressure, and cholesterol levels in clinical studies.
A proven GLP‑1 medication for chronic weight management.
GLP‑1 Receptor Agonist
Wegovy® mimics GLP‑1, a hormone that targets areas of the brain involved in appetite regulation, helping you feel fuller and more satisfied with less food.
Average 15% Weight Loss
In the STEP clinical trial program, patients on Wegovy® lost an average of 15% of their body weight over 68 weeks, with significant improvements starting within the first few months.
Once‑Weekly Injection
Wegovy® is administered as a once‑weekly subcutaneous injection using a pre‑filled pen. The dose is gradually escalated over 16–20 weeks to the maintenance dose.
Cardiovascular Benefits
Wegovy® is the first weight loss medication to receive FDA approval for reducing the risk of cardiovascular events in adults with obesity and established heart disease.
Zepbound® vs. Wegovy®
Both medications are highly effective. Our physicians will help you choose the best option based on your health profile and goals.
| Zepbound® | Wegovy® | |
|---|---|---|
| Generic Name | Tirzepatide | Semaglutide |
| Mechanism | Dual GIP/GLP‑1 | GLP‑1 |
| Average Weight Loss | Up to 22.5% | Up to 15% |
| Administration | Once‑weekly injection | Once‑weekly injection |
| FDA Approved for Weight Loss | ✓ | ✓ |
| Manufacturer | Eli Lilly | Novo Nordisk |
Safety & Side Effects
Our physicians monitor you closely throughout treatment to ensure your safety and comfort.
Common Side Effects
The most common side effects of Zepbound® and Wegovy® are gastrointestinal and include nausea, diarrhea, vomiting, and constipation. These are typically mild to moderate and tend to improve as your body adjusts to the medication.
Medical Monitoring
Our physicians start with a low dose and gradually increase it to help minimize side effects. Regular check‑ins allow us to adjust your treatment plan, manage any concerns, and ensure you’re progressing safely.
Who Should Not Take GLP‑1s
Zepbound® and Wegovy® are not recommended for patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or a history of pancreatitis. Our evaluation will screen for these and other contraindications.
FDA‑Approved & Evidence‑Based
Both Zepbound® and Wegovy® have undergone rigorous FDA review and are supported by large‑scale clinical trials involving thousands of participants. We only prescribe medications with strong safety and efficacy profiles.
Medication FAQs
Common questions about Zepbound®, Wegovy®, and GLP‑1 medications.
Both are excellent options. Zepbound® has shown higher average weight loss in clinical trials due to its dual‑action mechanism, while Wegovy® has additional FDA approval for cardiovascular risk reduction. The best choice depends on your health profile, which our physicians will evaluate during your consultation.
Both medications are administered as a once‑weekly subcutaneous injection using a simple pre‑filled pen. You can inject in the abdomen, thigh, or upper arm. Our team will teach you the proper technique at your first visit.
Most patients notice reduced appetite and early weight loss within the first 4‑8 weeks. As the dose is gradually increased to the target level over several weeks, weight loss typically accelerates. Significant results are usually seen at 3‑6 months.
Weight regain is possible if medication is discontinued without ongoing lifestyle changes. That’s why our program includes nutrition coaching and lifestyle support to help you build sustainable habits alongside medication.
Coverage for Zepbound® and Wegovy® varies by insurance plan. Many plans are now covering GLP‑1 medications for weight loss. Our team can help you navigate your insurance benefits, manufacturer savings programs, and self‑pay options.
Our physicians will review your complete medication list during your evaluation to check for interactions. GLP‑1 medications can affect how quickly your body absorbs other oral medications, so timing adjustments may be needed.
Find Out If Zepbound® or Wegovy® Is Right for You
Schedule a free consultation with our physicians to discuss your weight loss goals and determine the best medication for your needs.